CN103961362B - A kind of straw berry tomato lactone B application in preparing cancer therapy drug - Google Patents
A kind of straw berry tomato lactone B application in preparing cancer therapy drug Download PDFInfo
- Publication number
- CN103961362B CN103961362B CN201410209626.3A CN201410209626A CN103961362B CN 103961362 B CN103961362 B CN 103961362B CN 201410209626 A CN201410209626 A CN 201410209626A CN 103961362 B CN103961362 B CN 103961362B
- Authority
- CN
- China
- Prior art keywords
- lactone
- straw berry
- berry tomato
- therapy drug
- cancer therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of straw berry tomato lactone B application in preparing cancer therapy drug, the described compound that straw berry tomato lactone B is Formulas I structure, cancer therapy drug is prepared in described straw berry tomato lactone B and cisplatin combined application, the compound of Formulas I structure is as novel STAT3 inhibitor, simultaneously as chemical-therapy synergistic agent, synergy can be produced, it is possible to active anticancer is greatly improved during with cisplatin combined application.By result of the test, straw berry tomato lactone B can have active anticancer as novel STAT3 inhibitor, can be used for preparing cancer therapy drug.When straw berry tomato lactone B and Cisplatin, both can produce the strongest synergy, compared to being used alone cis-platinum, straw berry tomato lactone B and Cisplatin can embody higher active anticancer, straw berry tomato lactone B and Cisplatin are prepared cancer therapy drug and are conducive to the marketization to promote, and have broad application prospects.
Description
Technical field
The present invention relates to cancer therapy drug field, be specifically related to a kind of straw berry tomato lactone B and preparing cancer therapy drug
In application.
Background technology
In recent years, the incidence and mortality of malignant tumour is continuous ascendant trend, it has also become serious threat
The disease that human life is healthy.Chemotherapy is one of link indispensable in Multimodality Therapy of Malignant Tumors, but
It lacks targeting, and toxic and side effect is big, brings considerable distress to patient, and is easily generated during medication
MDR and cause the failure of chemotherapy.Therefore, improve the chemotherapeutic efficacy of chemotherapeutics, extend the life of patient
The phase of depositing is current problem demanding prompt solution.
Signal transducer and transcription activators 3 (signal transducer and activator of
Transcription3, STAT3) it is a kind of kinases, can be lived by upstream cytokine profiles, oncogene etc.
Changing, supporting property of the propagation of wide participation tumour, apoptosis, transfer invasion and attack, new vessels generate and immunologic escape
Etc. process.In normal cell, the activation of STAT3 is quick and of short duration, and in mankind's kinds of tumor cells
Middle STAT3 is sustained activation state.Existing document report, after STAT3 activation so that it is carboxyl terminal
Tyrosine residue phosphorylation, thus form homodimer or heterodimer is indexed into intracellular, in conjunction with
On target gene promoters regional DNA response element, start transcribing of target gene.Sustained activation
The expression of STAT3 regulation and control downstream several genes, as anti-apoptotic genes expression Bcl-2, Bcl-Xl, Mcl-1, XIAP,
Survivin and cycle regulating gene cyclin D1 and c-myc etc., enhance the apoptosis resistance of tumour cell
And proliferation activity.
Straw berry tomato (Physalis pubescens L.), has another name called ocean Miss or ground-cheery, for Solanaceae
(Solanaceae) the annual herb plant of Physalis (Physalis), is mainly distributed on three provinces in the northeast of China,
Shennong's Herbal is included the earliest.Modern pharmacology research show, straw berry tomato have anti-inflammatory, antibacterial,
Anticancer isoreactivity, physapubescin B (straw berry tomato lactone B) is the dry place calyx 95% from straw berry tomato
A kind of withanolide class reactive compound of isolated in ethanol extract, though there being document to report, it has
Antitumor activity, but it combines antineoplastic synergistic effect and there is not yet play-by-play with chemotherapeutic.
Application publication number is that the Chinese invention of 102516344A (Application No. 201110360206.1) is special
Profit application discloses a kind of compound with antitumor activity and its preparation method and application, and this has anti-
The compound of tumor promotion is the compound of Formulas I structure, extracts from straw berry tomato place calyx Extraction solvent, then
It is recrystallized to give after extracting, concentrate, eluting and there is antineoplastic compound.By Experimental Characterization, should
Compound has certain antitumor activity, however it is necessary that and studies its mechanism further, searches out
A kind of medicine with more preferable active anticancer.
Summary of the invention
The invention provides a kind of novel STAT3 inhibitor straw berry tomato lactone B (physapubescin B)
As the new opplication of chemical-therapy synergistic agent, it is specifically related to physapubescin B and combines with chemotherapeutic in preparation
Application in cancer therapy drug, physapubescin B can be remarkably reinforced the antitumor activity of chemotherapeutics.
To achieve these goals, the present invention takes techniques below scheme:
A kind of straw berry tomato lactone B application in preparing cancer therapy drug, described straw berry tomato lactone B is
The compound of Formulas I structure, cancer therapy drug is prepared in described straw berry tomato lactone B and cisplatin combined application；
In the present invention, the compound of Formulas I structure, as novel STAT3 inhibitor, increases simultaneously as chemotherapy
Effect agent, can produce synergy during with cisplatin combined application, it is possible to active anticancer is greatly improved.
The compound effects of Formulas I structure is in Non-small cell lung carcinoma cell NCI-H1975,24h and 48h
Detecting by MTT, result shows, the increasing of the suppression cell of the compound energy concentration dependant of Formulas I structure
Grow.
The compound effects of Formulas I structure, in Non-small cell lung carcinoma cell NCI-H1975, extracts total protein
After carry out immune-blotting method, this compound is to 705 tyrosine (Tyr705) phosphoric acid of STAT3 kinases
Change level has obvious inhibitory action, and its inhibitory action is concentration and time dependence downward trend.
But the STAT3 total protein expression that this compound is to human non-small cell lung cancer cell NCI-H1975
Without impact.
The present invention have detected the compound of Formulas I structure to human non-small cell lung cancer cell NCI-H1975's
The inhibition of Bcl-2, XIAP expression.By this cell of this compound effects, extract after 24 hours
Carrying out immune-blotting method after total protein, the compound of result display type I structure is to STAT3 downstream gene
Bcl-2, XIAP protein expression level has inhibitory action.
The compound effects of Formulas I structure is in human non-small cell lung cancer cell NCI-H1975, after 24 hours
Carrying out immune-blotting method after extracting total protein, result shows, the compound of Formulas I structure can substantially raise
The expression of shearing-type caspase9, caspase3, PARP of mitochondrial apoptosis lead label albumen.
Shown by above-mentioned result of the test, straw berry tomato lactone B of the present invention (i.e. physapubescin B,
The compound of Formulas I structure) can there is antitumor activity as novel STAT3 inhibitor, can be used for making
Standby cancer therapy drug.
The compound of Formulas I structure with cisplatin combined time, it is possible to mutually produce synergy, strengthen antitumor
Activity.
The compound of Formulas I structure can be combined with chemotherapeutics, as platinum kind anti-cancer drugs specifically can be selected for cis-platinum
Deng, anthracycline antibiotic specifically can be selected for adriamycin etc., and Difluoronucleosides kind anti-cancer drugs specifically can be selected for Ji Xi
The clinical often antineoplastic such as his shore.
And when the compound of Formulas I structure and Cisplatin, its synergy is the strongest, it is possible to be greatly improved anti-
The active anticancer of cancer drug.
Further preferably, described straw berry tomato lactone B and the mol ratio of cis-platinum are 2:1～4, above-mentioned
Mol ratio under, straw berry tomato lactone B (i.e. physapubescin B) and Cisplatin can produce stronger
Synergy.
Further preferred, described straw berry tomato lactone B and the mol ratio of cis-platinum are 6:3～8, this spy
Under fixed mol ratio, straw berry tomato lactone B (i.e. physapubescin B) and cis-platinum can produce higher association
Same-action.
Further preferred, described straw berry tomato lactone B and the mol ratio of cis-platinum are 2:1, and this is specific
Mol ratio under straw berry tomato lactone B (i.e. physapubescin B) and cis-platinum can produce the strongest association
Same-action.
The described cancer in cancer therapy drug be lung cancer, cancer of the stomach, breast cancer, colon cancer, oophoroma, liver cancer,
One or more of prostate cancer.
Described cancer therapy drug can be one or more in the form such as tablet, powder-injection.
Described cancer therapy drug is tablet, is made up of the raw material of following mass percent:
Further preferably, described cancer therapy drug is tablet, is made up of the raw material of following mass percent:
Compared with prior art, present invention have the advantage that
In the present invention, by result of the test, straw berry tomato lactone B can suppress as novel STAT3
Agent, has active anticancer, can be used for preparing cancer therapy drug.In vitro test shows physapubescin B
Combined chemotherapy medicine cis-platinum has obvious synergistic effect in killing malignant tumour.Described tumour include lung cancer,
One or more in cancer of the stomach, breast cancer, colon cancer etc..When straw berry tomato lactone B and Cisplatin
Time, both can produce the strongest synergy, compared to being used alone cis-platinum, straw berry tomato lactone B with
Cisplatin can embody higher active anticancer, and straw berry tomato lactone B and Cisplatin prepare anticarcinogen
Thing is conducive to the marketization to promote, and has broad application prospects.
Accompanying drawing explanation
Fig. 1 be in embodiment 1 physapubescin B to Non-small cell lung carcinoma cell NCI-H1975
Inhibited proliferation design sketch；
Fig. 2 be in embodiment 2 physapubescin B to Non-small cell lung carcinoma cell NCI-H1975
The inhibitory action design sketch of STAT3 phosphorylation level；
Fig. 3 be in embodiment 3 physapubescin B to Non-small cell lung carcinoma cell NCI-H1975
The inhibitory action design sketch of Bcl-2 and XIAP protein expression level；
Fig. 4 is that in embodiment 4, Non-small cell lung carcinoma cell NCI-H1975 is withered by physapubescin B
Die the action effect figure of lead label albumen PARP, cleaved-caspase3, cleaved-caspase9；
Fig. 5 is that in embodiment 5, physapubescin B is thin to Non-small cell lung carcinoma with cisplatin combined application
The inhibited proliferation design sketch of born of the same parents NCI-H292；
Fig. 6 is that in embodiment 6, physapubescin B is thin to Non-small cell lung carcinoma with cisplatin combined application
The streaming figure of born of the same parents' NCI-H292 apoptosis；
Wherein, PP31J is physapubescin B, and DDP is cis-platinum, and Ctrl is blank group.
Detailed description of the invention
The propagation of Non-small cell lung carcinoma cell NCI-H1975 is had by embodiment 1:physapubescin B
There is inhibitory action.
Specific implementation method is as follows:
Non-small cell lung carcinoma cell NCI-H1975 is placed in containing 10% (wt) hyclone (FBS)
RPMI1640 culture medium in cultivate (37 DEG C, 5%CO2), use conventional method digestion counting, take
Exponential phase cell presses 4 × 104The concentration of/ml inoculates 200 μ l in 96 well culture plates, and it is blank right to set
According to group, the medication group of physapubescin B (2.5 μMs, 5 μMs, 7.5 μMs, 10 μMs, 15 μMs) and molten
Agent dimethyl sulfoxide (DMSO) (DMSO) blank group, often organizes and all does 3 multiple holes.Treat that cell density reaches
60%-70%, is separately added into the physapubescin B of variable concentrations, after continuing to cultivate 24h and 48h,
Add tetramethyl azo azoles salt (MTT) the 20 μ l solution of 5mg/ml, after continuing to cultivate 4 hours, eventually
Only cultivating, exhaust culture medium as far as possible, every hole adds 150 μ l/ hole DMSO, shakes on oscillator plate
After swinging l0min, the Thermo full-automatic ELIASA of Varioskan Flash select wavelength 490nm survey
Fixed each hole light absorption value (A value), above-mentioned experiment is repeated 3 times.Calculate cell survival rate according to A value, calculate
Formula is: cell survival rate (%)=dosing group A value/negative control group A value × 100%.
Its experimental result as it is shown in figure 1, lung carcinoma cell NCI-H1975 with physapubescin B (0,
2.5 μMs, 5 μMs, 7.5 μMs, 10 μMs, 15 μMs) process 24h and 48h after, mtt assay detects
The impact of physapubescin B cell proliferation activity, result shows along with drug concentration increases, cell
Survival rate substantially reduces.
Embodiment 2:physapubescin B suppression Non-small cell lung carcinoma cell NCI-H1975's
705 tyrosine (Tyr of STAT3 kinases705) phosphorylation level.
Specific implementation method is as follows:
The NCI-H1975 RPMI1640 nutrient solution containing 10% (wt) FBS (GIBCO) is trained
Support.When cell grows to 70%-80%, addition variable concentrations (0,2.5 μM, 5 μMs, 10 μMs,
15 μMs) medicine physapubescin B, after 24h, collect cell in 15ml Eppendorf pipe,
800rpm, centrifugal 5min.During after abandoning supernatant, cell is transferred to the Eppendorf pipe of 1.5ml, 8000rpm,
Centrifugal 5min.Abandon clean supernatant, add the RIPA lysate containing 1% (wt) phosphorglase inhibitor,
After piping and druming uniformly, cell lysis 30min, every 10min shake once on ice.After cell fully cracks,
13000rpm, centrifugal 10min, take supernatant, after BCA protein quantification kit measurement protein concentration,
Equal-volume adds 2 × SDS sample-loading buffer, 100 DEG C of water-bath sex change 5min, cooled on ice, is system
The cell protein sample liquid got ready.Molecular size range preparation (8%-12%) polypropylene according to detection albumen
Acrylamide gel, is loaded rear electrophoresis, subsequently by electrophoretic transfer (constant current 250mA, 2h) to PVDF
On film.After transfer, 5% skimmed milk power room temperature 25 DEG C is closed 2 hours, an anti-(confining liquid dilution
P-STAT3-tyr to 1:1000(705), STAT3, antibody is purchased from CST company) 4 DEG C hatched
At night, by 1 × TBST buffer solution for cleaning 3 times, 10min/ time, subsequently film is resisted with two marked with HRP
Hatching, room temperature 25 DEG C is hatched 2 hours, then by film with 1 × TBST clean 30min, 10min/ time.
Gel imaging system Chemi Dox XRS is utilized to gather image, protein-bonded expression water in detection membrane
Flat.
Its experimental result as in figure 2 it is shown, lung carcinoma cell NCI-H1975 with physapubescin B (0,
2.5 μMs, 5 μMs, 10 μMs, 15 μMs) process 4h and 15 μMs of physapubescin B process (0,
0.5h, 1h, 2h, 4h) after, Western Blot detects p-STAT3-tyr(705), the expression of STAT3,
Result shows, physapubescin B can substantially suppress STAT3-tyr(705)Phosphorylation level, it presses down
Processing procedure degree is time and concentration dependent.
Embodiment 3:physapubescin B lowers human non-small cell lung cancer cell NCI-H1975
The protein expression level of STAT3 downstream gene Bcl-2 and XIAP.
Specific implementation method is as follows:
The NCI-H1975 RPMI1640 nutrient solution containing 10% (wt) FBS (GIBCO) is trained
Support.When cell grows to 70%-80%, addition variable concentrations (0,2.5 μM, 5 μMs, 10 μMs,
15 μMs) medicine, after 24h, collect cell in 15ml Eppendorf pipe, 800rpm, centrifugal
5min.During after abandoning supernatant, cell is transferred to the Eppendorf pipe of 1.5ml, 8000rpm, centrifugal 5min.
Abandon clean supernatant, add the RIPA lysate containing 1% (wt) phosphorglase inhibitor, after piping and druming uniformly
Cell lysis 30min on ice, every 10min shake once.After cell fully cracks, 13000rpm,
Centrifugal 10min, takes supernatant, and after BCA protein quantification kit measurement protein concentration, equal-volume adds
Enter 2 × SDS sample-loading buffer, 100 DEG C of water-bath sex change 5min, cooled on ice, be prepare thin
Born of the same parents' albumen sample liquid.Molecular size range preparation (8%-12%) polyacrylamide gel according to detection albumen,
Sample-adding rear electrophoresis, subsequently by electrophoretic transfer (constant current 250mA, 2h) to pvdf membrane.Transfer
After, 5% (wt) skimmed milk power room temperature 25 DEG C closes 2 hours, one anti-(confining liquid is diluted to 1:
Bcl-2, XIAP, β-actin of 1000, antibody is purchased from CST company) 4 DEG C of overnight incubation, use
1 × TBST buffer solution for cleaning 3 times, 10min/ time, hatches anti-with two marked with HRP for film subsequently,
Room temperature 25 DEG C is hatched 2 hours, then by film with 1 × TBST clean 30min, 10min/ time.Utilize solidifying
Glue imaging system Chemi Dox XRS gathers image, protein-bonded expression in detection membrane.
Its experimental result as it is shown on figure 3, physapubescin B (0,2.5 μM, 5 μMs, 10 μMs,
15 μMs) process cell 24h, Western Blot result show along with concentration increase, STAT3 downstream
The expression of anti-apoptotic proteins Bcl-2, XIAP is decreased obviously.
Embodiment 4:physapubescin B is to human non-small cell lung cancer's cell NCI-H1975 apoptosis
The impact of labelled protein.
Specific implementation method is basically identical with embodiment 3.
Its experimental result as shown in Figure 4, by human non-small cell lung cancer cell NCI-H1975 (2.5 μMs,
5 μMs, 10 μMs, 15 μMs) process 24h after, with blank for comparison, leach protein, Western Blot
Detection Cle-caspase3/9, Cle-PARP, β-actin, test result indicate that, apoptosis labelled protein
Cle-caspase3/9, Cle-PARP are significantly raised, and physapubescin B can substantially induce its apoptosis.
Embodiment 5:physapubescin B combines suppression human non-small cell's lung with chemotherapeutic (cis-platinum)
The propagation of cancer cell NCI-H292.
Specific implementation method is as follows:
Non-small cell lung carcinoma cell NCI-H292 is placed in containing 10% (wt) hyclone (FBS)
RPMI1640 in cultivate (37 DEG C, 5%CO2), use conventional method digestion counting, life of taking the logarithm
Long-term cell presses 4 × 104The concentration of/ml inoculates 200 μ l in 96 well culture plates, set blank group,
Variable concentrations physapubescin B (7.5 μMs, 10 μMs) combines group and solvent two with cis-platinum (10 μMs)
Methyl sulfoxide (DMSO) blank group, often organizes and all does 3 multiple holes.Treat that cell density reaches 60%-70%,
By being grouped dosing above, after continuing to cultivate 24 hours, add tetramethyl azo azoles salt (MTT) of 5mg/ml
20 μ l solution, continue to cultivate 4 hours, terminate cultivating, exhaust culture medium as far as possible, and every hole adds 150 μ l/
Hole DMSO is after the l0min that vibrates on oscillator plate, complete certainly at Thermo Varioskan Flash
Selecting wavelength 490nm to measure each hole light absorption value (A value) on dynamic ELIASA, above-mentioned experiment is repeated 3 times.Root
Calculating cell survival rate according to A value, computing formula is: cell survival rate (%)=dosing group A value/feminine gender
Control group A value × 100%.
Its experimental result is as it is shown in figure 5, physapubescin B (7.5 μMs～10 μMs) cis-platinum (10 μMs)
In selected dosage range, both use in conjunction can work in coordination with suppression human non-small cell lung cancer's cell
The propagation of NCI-H292, wherein, in Fig. 5, PP31J is physapubescin B, and DDP is cis-platinum,
When its physapubescin B10 μM and cis-platinum 10 μMs, cell survival rate is relatively low, is 25%, explanation
Human non-small cell lung cancer cell NCI-H292 there is is good inhibitory action, the most unexpectedly sends out
Existing, when physapubescin B8 μM and cis-platinum 4 μMs, cell survival rate is 25%, it is seen then that should
Higher working in coordination with can be had between straw berry tomato lactone B (physapubescin B) and the cis-platinum of special ratios
Effect, it has the most excellent inhibitory action to cancer cell.
Embodiment 6:physapubescin B and chemotherapeutic (cis-platinum) combined induction human non-small cell's lung
The apoptosis of cancer cell NCI-H292.
Specific implementation method is as follows:
Non-small cell lung carcinoma cell NCI-H292 is placed in the RPMI containing 10% hyclone (FBS)
(37 DEG C, 5%CO is cultivated in 16402), use conventional method digestion counting, take the logarithm growth period
NCI-H292 cell, with 8 × 104/ hole is incubated in 12 orifice plates, and cell attachment was carried out after 24 hours
Dosing, dosing is 0, physapubescin B10 μM, cis-platinum 10 μMs and physapubescin B
It is physapubescin B10 μM and cis-platinum 10 μMs with the drug regimen of cis-platinum, puts into incubator and incubate
Educate 24 hours.With the collected by trypsinisation cell without EDTA after 24 hours, 800r/min is centrifuged 5min,
Abandoning supernatant, PBS washes, centrifugal.Take 500ul1 × Binding Buffer in kit to combine buffer solution and make
Cell Eddy diffusion, often pipe mixes after adding 5ulAnnexin V-FITC, then adds 10ul iodate third
Ingot, mixing, under room temperature, lucifuge reaction 5min, puts into flow cytometer and carries out apoptosis detection.
Its experimental result as shown in Figure 6, select by physapubescin B (10 μMs) cis-platinum (10 μMs)
In dosage range, both use in conjunction can work in coordination with suppression human non-small cell lung cancer cell NCI-H292's
Apoptosis.
Embodiment 7 (preparation of cancer therapy drug tablet)
1) weigh straw berry tomato lactone B (42.30g, 0.09176mol), cis-platinum (13.77g, 0.04588mol),
The binder of 8g, the carboxyrnethyl starch sodium of 16g, the starch of 24g and the magnesium stearate of 2g；Wherein, bind
Agent is by the Hydroxypropyl methylcellulose aqueous solution that the mass percent containing Hydroxypropyl methylcellulose is 8% and amyloid
Mass percent be 8% starch slurry (starch and water composition) mix according to weight ratio 3:10.Carboxylic
First sodium starch uses as disintegrant.
2) by straw berry tomato lactone B (42.30g, 0.09176mol) weighed, cis-platinum (13.77g, 0.04588
Mol), starch 24g, carboxyrnethyl starch sodium 12g be placed in mixing channel mixing 25min, be subsequently adding bonding
Agent 8g mixes softwood processed, pelletizes after 14 mesh sieves, the dried mistake 14 whole grain of mesh sieve, and addition weighs
The carboxyrnethyl starch sodium of magnesium stearate 2g and 4g, tabletted after mixing, i.e. complete antineoplastic tablet
Preparation；The cancer therapy drug tablet format of preparation is 0.5g (in terms of the total amount of every tablet of antineoplastic tablet).
It is 56g that above-mentioned cis-platinum replaces with straw berry tomato lactone B, the i.e. total amount of straw berry tomato lactone B, weight
Multiple step 1) and step 2), obtain straw berry tomato lactone B tablet.
Above-mentioned straw berry tomato lactone B is replaced with cis-platinum, i.e. the total amount of cis-platinum is 56g, repeats step 1)
With step 2), obtain cis-platinum tablet.
Carry out cell survival rate experiment as described in Example 5, respectively by cancer therapy drug tablet 0.5g, hair
Wintercherry lactone B tablet 0.5g, cis-platinum tablet 0.5g are dissolved in 40L water, use straw berry tomato lactone B sheet
The cell survival rate of agent is 70%, and the cell survival rate using cis-platinum tablet is 75%, uses cancer therapy drug
Cell survival rate be 22%.Visible, by straw berry tomato lactone B and Cisplatin (particularly in straw berry tomato
The mol ratio of ester B and cis-platinum is 2:1) prepare cancer therapy drug tablet and can produce the strongest collaborative work
With, the cancer therapy drug tablet of preparation has extraordinary active anticancer.
Claims (6)
1. straw berry tomato lactone B and cisplatin combined application in preparing cancer therapy drug, it is characterised in that
The described compound that straw berry tomato lactone B is Formulas I structure；
Described straw berry tomato lactone B and the mol ratio of cis-platinum are 2:1～4；
The described cancer in cancer therapy drug be lung cancer, cancer of the stomach, breast cancer, colon cancer, oophoroma, liver cancer,
One or more of prostate cancer.
Application the most according to claim 1, it is characterised in that described straw berry tomato lactone B and
The mol ratio of cis-platinum is 6:3～8.
Application the most according to claim 2, it is characterised in that described straw berry tomato lactone B and
The mol ratio of cis-platinum is 2:1.
Application the most according to claim 1, it is characterised in that described cancer therapy drug be tablet,
One or both in powder-injection.
Application the most according to claim 1, it is characterised in that described cancer therapy drug is tablet,
It is made up of the raw material of following mass percent:
Application the most according to claim 5, it is characterised in that described cancer therapy drug is tablet,
It is made up of the raw material of following mass percent:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410209626.3A CN103961362B (en) | 2014-05-16 | 2014-05-16 | A kind of straw berry tomato lactone B application in preparing cancer therapy drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410209626.3A CN103961362B (en) | 2014-05-16 | 2014-05-16 | A kind of straw berry tomato lactone B application in preparing cancer therapy drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103961362A CN103961362A (en) | 2014-08-06 |
| CN103961362B true CN103961362B (en) | 2016-08-24 |
Family
ID=51231685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410209626.3A Active CN103961362B (en) | 2014-05-16 | 2014-05-16 | A kind of straw berry tomato lactone B application in preparing cancer therapy drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103961362B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105524135B (en) * | 2015-12-25 | 2019-11-22 | 天津中医药大学 | The preparation method and its application in preparation of anti-tumor drugs of straw berry tomato lactone |
| CN111377994A (en) * | 2018-12-28 | 2020-07-07 | 南开大学 | Seven withanolides compounds from cape gooseberry and preparation method and application thereof |
| CN113730418A (en) * | 2021-09-27 | 2021-12-03 | 浙江中医药大学附属第一医院 | Application of physalilactone B in preparation of medicine for treating diseases associated with cytokine storm |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102516344A (en) * | 2011-11-14 | 2012-06-27 | 浙江大学 | Compound with antitumor activity and preparation method and application thereof |
-
2014
- 2014-05-16 CN CN201410209626.3A patent/CN103961362B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102516344A (en) * | 2011-11-14 | 2012-06-27 | 浙江大学 | Compound with antitumor activity and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103961362A (en) | 2014-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gao et al. | Inhibition of STAT3 and ErbB2 suppresses tumor growth, enhances radiosensitivity, and induces mitochondria-dependent apoptosis in glioma cells | |
| Dong et al. | Bufadienolide compounds sensitize human breast cancer cells to TRAIL-induced apoptosis via inhibition of STAT3/Mcl-1 pathway | |
| Chan et al. | Polyphyllin D, a steroidal saponin from Paris polyphylla, inhibits endothelial cell functions in vitro and angiogenesis in zebrafish embryos in vivo | |
| Mandalapu et al. | Synthesis and biological evaluation of some novel triazole hybrids of curcumin mimics and their selective anticancer activity against breast and prostate cancer cell lines | |
| CN103961362B (en) | A kind of straw berry tomato lactone B application in preparing cancer therapy drug | |
| Xu et al. | Activation of the unfolded protein response contributed to the selective cytotoxicity of oroxylin A in human hepatocellular carcinoma HepG2 cells | |
| Ma et al. | Tetrandrine suppresses human glioma growth by inhibiting cell survival, proliferation and tumour angiogenesis through attenuating STAT3 phosphorylation | |
| CN109758486A (en) | Ganodenna Lucidum P.E is preparing the application in artitumor multi-medicine-resistant medicine | |
| CN104327152A (en) | Triptolide derivatives and application thereof | |
| Singh et al. | Screening of multi-targeted natural compounds for receptor tyrosine kinases inhibitors and biological evaluation on cancer cell lines, in silico and in vitro | |
| Xu et al. | Corydalis yanhusuo WT Wang extract inhibits MCF-7 cell proliferation by inducing cell cycle G2/M arrest | |
| CN106631804B (en) | A kind of compound and the preparation method and application thereof isolated from Labiatae Rabdosia plant | |
| CN103230401A (en) | Application of triptonide to anti-angiogenesis drugs | |
| Han et al. | 8-Cetylcoptisine, a new coptisine derivative, induces mitochondria-dependent apoptosis and G0/G1 cell cycle arrest in human A549 cells | |
| Dou et al. | Atractylenolide II induces cell cycle arrest and apoptosis in breast cancer cells through ER pathway. | |
| Wang et al. | A novel synthetic Asiatic acid derivative induces apoptosis and inhibits proliferation and mobility of gastric cancer cells by suppressing STAT3 signaling pathway | |
| CN104546843A (en) | Application of pyrazole hydrazone derivative in preparation of anti-breast cancer drug | |
| CN103784435B (en) | The application of physalin A in preparation JAK2-STAT3 signal pathway inhibitor and antitumor drug | |
| CN102961374B (en) | Application of compound and STAT3 (Signal Transducer and Activator of Transcription) inhibitor | |
| CN111329849B (en) | Pharmaceutical composition of fingolimod hydrochloride and curcumenol and application of pharmaceutical composition in preparation of anti-oral cancer drugs | |
| CN101933964A (en) | Application of conyza blinii total saponins for preparing anti-neoplastic drug | |
| CN103690519A (en) | Application of salvianolic acid A in preparation of medicine for treating tumour multi-drug resistance | |
| CN102552300B (en) | Application of monensin as STAT 3 signal specific inhibitor | |
| Zhang et al. | 5-Acetamido-1-(methoxybenzyl) isatin inhibits tumor cell proliferation, migration, and angiogenesis | |
| CN103012394B (en) | Rhodanine derivative and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 311400, No. 13, No. 1, Dongzhou industrial function zone, Fuyang District, Zhejiang, Hangzhou Applicant after: HANGZHOU KEXING BIOCHEM. CO., LTD. Address before: 311400, No. thirteen, No. 1, Dongzhou industrial function zone, Hangzhou, Zhejiang, Fuyang Applicant before: Fuyang Kexing Biochemical Co., Ltd. |
|
| COR | Change of bibliographic data | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220228 Address after: 311400 No. 1, No. 13 Road, Dongzhou industrial functional zone, Dongzhou street, Fuyang District, Hangzhou City, Zhejiang Province Patentee after: Zhejiang Meixin Holding Co.,Ltd. Address before: No.3111, Fuzhou Industrial Park, Hangzhou Patentee before: HANGZHOU KEXING BIOCHEM Co.,Ltd. |
|
| TR01 | Transfer of patent right |